Rahul K Reddy1, Dante J Pieramici2, Shamika Gune3, Avanti Ghanekar3, Na Lu3, Carlos Quezada-Ruiz3, Caroline R Baumal4. 1. Associated Retina Consultants, Phoenix, Arizona. Electronic address: rreddy375@yahoo.com. 2. California Retina Consultants, Santa Barbara, California. 3. Genentech, Inc, South San Francisco, California. 4. New England Eye Center, Tufts University School of Medicine, Boston, Massachusetts.
Abstract
PURPOSE: To determine whether there are baseline characteristics that distinguish patients with diabetic macular edema (DME) with coexisting macular nonperfusion (MNP) at baseline and assess these patients' potential to achieve favorable visual acuity (VA), anatomic, and diabetic retinopathy (DR) outcomes over 24 months. DESIGN: Post hoc analysis of RIDE/RISE, 2 phase 3, parallel, randomized, multicenter, double-masked trials (ClinicalTrials.gov: NCT00473382; NCT00473330). PARTICIPANTS: Study eyes with best-corrected VA (BCVA)/fluorescein angiogram (FA) data at baseline. METHODS: To measure MNP, the Early Treatment for Diabetic Retinopathy Study (ETDRS) grid was overlaid on FAs of the macula. The MNP area was calculated by estimating the percentage of capillary loss in the central, inner, and outer subfields and converting into disc areas (DAs) using a software algorithm. Summary statistics and P values, respectively, were provided for all outcomes and comparisons of interest. MAIN OUTCOME MEASURES: Baseline characteristics; MNP area, BCVA, and central subfield thickness (CST) at months 12 and 24; and incidence of study eyes with ≥2-step DR improvement at months 3, 6, 12, 18, and 24. RESULTS:Baseline MNP was detected in 28.2%, 25.8%, and 26.3% of study eyes in the ranibizumab 0.3 mg (n = 213), ranibizumab 0.5 mg (n = 225), and sham (n = 228) arms, respectively. At baseline, patients with MNP were younger and had shorter diabetes duration, worse vision, increased CST, and worse DR severity (P values < 0.01 vs. those without MNP). In the ranibizumab 0.3 mg arm, eyes with baseline MNP had lower mean baseline BCVA (53.4 vs. 57.2 ETDRS letters for those without baseline MNP; P = 0.05), but mean BCVA gain at month 24 was comparable (+15.6 vs. +13.4 ETDRS letters, respectively; P = 0.2). Eyes with baseline MNP had increased CST at baseline, but experienced a greater decrease in CST by month 24. The proportion of eyes with ≥2-step DR improvement was greater for eyes with versus without baseline MNP in each ranibizumab arm. CONCLUSIONS: Despite having worse vision/increased CST versus those without baseline MNP, eyes with concurrent DME and baseline MNP entering RIDE/RISE experienced robust VA and anatomic improvement with ranibizumab and therefore should not be excluded from therapy.
RCT Entities:
PURPOSE: To determine whether there are baseline characteristics that distinguish patients with diabetic macular edema (DME) with coexisting macular nonperfusion (MNP) at baseline and assess these patients' potential to achieve favorable visual acuity (VA), anatomic, and diabetic retinopathy (DR) outcomes over 24 months. DESIGN: Post hoc analysis of RIDE/RISE, 2 phase 3, parallel, randomized, multicenter, double-masked trials (ClinicalTrials.gov: NCT00473382; NCT00473330). PARTICIPANTS: Study eyes with best-corrected VA (BCVA)/fluorescein angiogram (FA) data at baseline. METHODS: To measure MNP, the Early Treatment for Diabetic Retinopathy Study (ETDRS) grid was overlaid on FAs of the macula. The MNP area was calculated by estimating the percentage of capillary loss in the central, inner, and outer subfields and converting into disc areas (DAs) using a software algorithm. Summary statistics and P values, respectively, were provided for all outcomes and comparisons of interest. MAIN OUTCOME MEASURES: Baseline characteristics; MNP area, BCVA, and central subfield thickness (CST) at months 12 and 24; and incidence of study eyes with ≥2-step DR improvement at months 3, 6, 12, 18, and 24. RESULTS: Baseline MNP was detected in 28.2%, 25.8%, and 26.3% of study eyes in the ranibizumab 0.3 mg (n = 213), ranibizumab 0.5 mg (n = 225), and sham (n = 228) arms, respectively. At baseline, patients with MNP were younger and had shorter diabetes duration, worse vision, increased CST, and worse DR severity (P values < 0.01 vs. those without MNP). In the ranibizumab 0.3 mg arm, eyes with baseline MNP had lower mean baseline BCVA (53.4 vs. 57.2 ETDRS letters for those without baseline MNP; P = 0.05), but mean BCVA gain at month 24 was comparable (+15.6 vs. +13.4 ETDRS letters, respectively; P = 0.2). Eyes with baseline MNP had increased CST at baseline, but experienced a greater decrease in CST by month 24. The proportion of eyes with ≥2-step DR improvement was greater for eyes with versus without baseline MNP in each ranibizumab arm. CONCLUSIONS: Despite having worse vision/increased CST versus those without baseline MNP, eyes with concurrent DME and baseline MNP entering RIDE/RISE experienced robust VA and anatomic improvement with ranibizumab and therefore should not be excluded from therapy.
Authors: Osama A Sorour; Almyr S Sabrosa; A Yasin Alibhai; Malvika Arya; Akihiro Ishibazawa; Andre J Witkin; Caroline R Baumal; Jay S Duker; Nadia K Waheed Journal: Int Ophthalmol Date: 2019-05-22 Impact factor: 2.031
Authors: Jesse J Jung; Daryle Jason G Yu; Anne Zeng; Michael H Chen; Yue Shi; Marco Nassisi; Kenneth M Marion; Srinivas R Sadda; Quan V Hoang Journal: Ophthalmol Retina Date: 2020-05-07
Authors: Ahmed Roshdy Alagorie; Muneeswar Gupta Nittala; Swetha Velaga; Brenda Zhou; Alexander M Rusakevich; Charles C Wykoff; SriniVas R Sadda Journal: JAMA Ophthalmol Date: 2020-08-01 Impact factor: 7.389
Authors: Charles C Wykoff; Hannah J Yu; Robert L Avery; Justis P Ehlers; Ramin Tadayoni; SriniVas R Sadda Journal: Eye (Lond) Date: 2022-01-11 Impact factor: 3.775
Authors: Joseph R Abraham; Charles C Wykoff; Sruthi Arepalli; Leina Lunasco; Hannah J Yu; Alison Martin; Christopher Mugnaini; Ming Hu; Jamie Reese; Sunil K Srivastava; David M Brown; Justis P Ehlers Journal: Br J Ophthalmol Date: 2021-06-07 Impact factor: 5.908
Authors: Osama A Sorour; Nihaal Mehta; Caroline R Baumal; Akihiro Ishibazawa; Keke Liu; Eleni K Konstantinou; Sarah Martin; Phillip Braun; A Yasin Alibhai; Malvika Arya; Andre J Witkin; Jay S Duker; Nadia K Waheed Journal: Eye Vis (Lond) Date: 2020-06-01